[{"orgOrder":0,"company":"MicuRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase III","graph3":"MicuRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MicuRx \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Contezolid Acefosamil","moa":"Bacterial 70S ribosome","graph1":"Podiatry","graph2":"Phase I","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"MicuRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MicuRx Pharmaceuticals \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Contezolid Acefosamil

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : MRX-4 (contezolid acefosamil) is being evaluating in the late-stage clinical trials studies for the treatment of patients suffering from Diabetic Foot Infection.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          February 25, 2025

                          Lead Product(s) : Contezolid Acefosamil

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          MicuRx

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          MicuRx

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Contezolid Acefosamil is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          May 11, 2022

                          Lead Product(s) : Contezolid Acefosamil

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          MicuRx

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          MicuRx

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Contezolid Acefosamil is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Skin Diseases, Bacterial.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          November 20, 2018

                          Lead Product(s) : Contezolid Acefosamil

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          MicuRx

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          MicuRx

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : MRX-4 is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          January 26, 2017

                          Lead Product(s) : Contezolid Acefosamil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Worldwide Clinical Trials

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          MicuRx

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          MicuRx

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : MRX-4 is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          January 26, 2017

                          Lead Product(s) : Contezolid Acefosamil

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Worldwide Clinical Trials

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank